Proteostasis Therapeutics, Inc. (PTI): Price and Financial Metrics
PTI Price/Volume Stats
| Current price | $1.11 | 52-week high | $2.72 |
| Prev. close | $1.15 | 52-week low | $0.87 |
| Day low | $1.10 | Volume | 2,110,100 |
| Day high | $1.20 | Avg. volume | 1,036,509 |
| 50-day MA | $1.10 | Dividend yield | N/A |
| 200-day MA | $1.30 | Market Cap | 57.93M |
PTI Stock Price Chart Interactive Chart >
Proteostasis Therapeutics, Inc. (PTI) Company Bio
Proteostasis Therapeutics, Inc., a biopharmaceutical company, develops therapeutics to treat protein conformational diseases. The company offers disease-modifying therapeutics for cystic fibrosis; and also develops treatments for diseases caused by an imbalance in the proteostasis network and characterized by defects in protein folding, trafficking, and clearance, including genetic, neurodegenerative, and retinal degenerative diseases. The company was founded in 2006 and is based in Cambridge, Massachusetts.
Latest PTI News From Around the Web
Below are the latest news stories about Proteostasis Therapeutics Inc that investors may wish to consider to help them evaluate PTI as an investment opportunity.
Here's Why We're Watching Proteostasis Therapeutics' (NASDAQ:PTI) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split RatioProteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at 9:00 a.m. Eastern Time on December 22, 2020 (the "Special Meeting"), its stockholders approved all of the proposals related to the merger (the "Merger") as contemplated by the Agreement and Plan of Merger and Reorganization, dated August 22, 2020, as amended, by and among Proteostasis, Yumanity Holdings, LLC ("Holdings"), Yumanity Therapeutics, Inc. ("Yumanity"), a wholly-owned subsidiary of Holdings, and Pangolin Merger Sub, a wholly-owned subsidiary of Proteostasis ("Merger Sub") (the "Merger Agreement"), including (i) the issuance of Proteostasis common stock in the Merger i... |
Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with ProteostasisLeading institutional investors commit $33.6 million through a common stock private investment in public equity (“PIPE”) led by Fidelity Management & Research Company, LLC and Invus Proteostasis plans to adjourn its special meeting of stockholders to December 22, 2020BOSTON, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, and Proteostasis Therapeutics, Inc. (Nasdaq: PTI) today announced that Proteostasis has entered into a definitive agreement for the sale of its Common Stock in a private placement led by Fidelity Management & Research Company, LLC and Invus and including participation from Sphera Biotech, Stonepi... |
Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm – MVC, PTI, CGIX, STNDNEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: MVC Capital, Inc. (NYSE: MVC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Barings BDC, Inc. Under the terms of the merger agreement, MVC Capital shareholders will receive 0.94024 shares of Barings BDC and $0.39492 in cash for each share of MVC Capital stock. If you are an MVC Capital shareholder, click here to learn more about your legal rights and options.Proteostasis Therapeutics, Inc. (NASDAQ: PTI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Yumanity Therapeutics. If you are a Proteostasis sharehol... |
Do Hedge Funds Love Proteostasis Therapeutics, Inc. (PTI)?The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […] |
PTI Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 14.43% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | -29.63% |
Continue Researching PTI
Want to see what other sources are saying about Proteostasis Therapeutics Inc's financials and stock price? Try the links below:Proteostasis Therapeutics Inc (PTI) Stock Price | Nasdaq
Proteostasis Therapeutics Inc (PTI) Stock Quote, History and News - Yahoo Finance
Proteostasis Therapeutics Inc (PTI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...